(Q36192769)

12 August 2017

1 reference

title

Miltefosine to treat leishmaniasis (English)

1 reference

12 August 2017

1 reference

Jonathan Berman

1

1 reference

PubMed ID

16013987

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

1 reference

12 August 2017

6

1 reference

12 August 2017

8

1 reference

12 August 2017

1381-1388

1 reference

Estimation of population at risk of infection and number of cases of Leishmaniasis

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Trial of oral miltefosine for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1381

10.1517/14656566.6.8.1381

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16013987